GC Biopharma Statistics

Total Valuation

GC Biopharma has a market cap or net worth of KRW 1.36 trillion. The enterprise value is 2.39 trillion.

Market Cap	1.36T
Enterprise Value	2.39T

Important Dates

The next estimated earnings date is Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

GC Biopharma has 11.41 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	11.41M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.95%
Owned by Institutions (%)	17.25%
Float	5.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	104.02
PS Ratio	0.81
PB Ratio	0.92
P/TBV Ratio	1.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.91, with an EV/FCF ratio of -27.98.

EV / Earnings	-90.97
EV / Sales	1.42
EV / EBITDA	20.91
EV / EBIT	71.82
EV / FCF	-27.98

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.56.

Current Ratio	1.56
Quick Ratio	0.55
Debt / Equity	0.56
Debt / EBITDA	7.32
Debt / FCF	-9.69
Interest Coverage	0.79

Financial Efficiency

Return on equity (ROE) is -2.82% and return on invested capital (ROIC) is 0.88%.

Return on Equity (ROE)	-2.82%
Return on Assets (ROA)	0.74%
Return on Invested Capital (ROIC)	0.88%
Return on Capital Employed (ROCE)	1.62%
Revenue Per Employee	836.18M
Profits Per Employee	-13.08M
Employee Count	2,009
Asset Turnover	0.62
Inventory Turnover	1.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.11% in the last 52 weeks. The beta is 1.41, so GC Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.41
52-Week Price Change	+3.11%
50-Day Moving Average	124,808.00
200-Day Moving Average	144,258.50
Relative Strength Index (RSI)	42.69
Average Volume (20 Days)	23,181

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Biopharma had revenue of KRW 1.68 trillion and -26.28 billion in losses. Loss per share was -2,302.62.

Revenue	1.68T
Gross Profit	480.54B
Operating Income	32.04B
Pretax Income	-41.11B
Net Income	-26.28B
EBITDA	113.07B
EBIT	32.04B
Loss Per Share	-2,302.62

Full Income Statement

Balance Sheet

The company has 24.00 billion in cash and 828.14 billion in debt, giving a net cash position of -804.15 billion or -70,457.79 per share.

Cash & Cash Equivalents	24.00B
Total Debt	828.14B
Net Cash	-804.15B
Net Cash Per Share	-70,457.79
Equity (Book Value)	1.48T
Book Value Per Share	109,754.26
Working Capital	432.36B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -53.46 billion and capital expenditures -31.99 billion, giving a free cash flow of -85.45 billion.

Operating Cash Flow	-53.46B
Capital Expenditures	-31.99B
Free Cash Flow	-85.45B
FCF Per Share	-7,487.13

Full Cash Flow Statement

Margins

Gross margin is 28.61%, with operating and profit margins of 1.91% and -1.56%.

Gross Margin	28.61%
Operating Margin	1.91%
Pretax Margin	-2.45%
Profit Margin	-1.56%
EBITDA Margin	6.73%
EBIT Margin	1.91%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.26%.

Dividend Per Share	1,500.00
Dividend Yield	1.26%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	1.26%
Earnings Yield	-1.93%
FCF Yield	-6.29%

Dividend Details

Stock Splits

The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.

Last Split Date	Jun 7, 2013
Split Type	Forward
Split Ratio	1.05

Scores

GC Biopharma has an Altman Z-Score of 1.98. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.98
Piotroski F-Score	n/a